KR20120108071A - Composition containing soybean by product for anti-obesity - Google Patents
Composition containing soybean by product for anti-obesity Download PDFInfo
- Publication number
- KR20120108071A KR20120108071A KR1020110025594A KR20110025594A KR20120108071A KR 20120108071 A KR20120108071 A KR 20120108071A KR 1020110025594 A KR1020110025594 A KR 1020110025594A KR 20110025594 A KR20110025594 A KR 20110025594A KR 20120108071 A KR20120108071 A KR 20120108071A
- Authority
- KR
- South Korea
- Prior art keywords
- soybean
- fat
- composition
- obesity
- preventing
- Prior art date
Links
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 149
- 244000068988 Glycine max Species 0.000 title claims abstract description 148
- 239000006227 byproduct Substances 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000003579 anti-obesity Effects 0.000 title description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 67
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 47
- 208000008589 Obesity Diseases 0.000 claims abstract description 44
- 235000020824 obesity Nutrition 0.000 claims abstract description 44
- 230000004069 differentiation Effects 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims abstract description 31
- 238000009825 accumulation Methods 0.000 claims abstract description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 235000013527 bean curd Nutrition 0.000 claims abstract description 13
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims abstract description 11
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims abstract description 11
- 108010018763 Biotin carboxylase Proteins 0.000 claims abstract description 11
- 238000002791 soaking Methods 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 8
- 239000005862 Whey Substances 0.000 claims abstract description 7
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 7
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 238000007654 immersion Methods 0.000 claims description 51
- 235000005911 diet Nutrition 0.000 claims description 48
- 230000037213 diet Effects 0.000 claims description 48
- 238000012545 processing Methods 0.000 claims description 23
- 201000010063 epididymitis Diseases 0.000 claims description 18
- 108010016731 PPAR gamma Proteins 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 210000004185 liver Anatomy 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 9
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000007850 degeneration Effects 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 235000013736 caramel Nutrition 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 230000004132 lipogenesis Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 abstract description 21
- 210000000229 preadipocyte Anatomy 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 abstract 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 abstract 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 1
- 238000007598 dipping method Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 48
- 235000019197 fats Nutrition 0.000 description 47
- 235000009200 high fat diet Nutrition 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 18
- 235000021590 normal diet Nutrition 0.000 description 17
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 210000000579 abdominal fat Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 108090000059 Complement factor D Proteins 0.000 description 6
- 102000003706 Complement factor D Human genes 0.000 description 6
- 108010047909 Resistin Proteins 0.000 description 6
- 102000007156 Resistin Human genes 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000010603 microCT Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000014777 Adipokines Human genes 0.000 description 4
- 108010078606 Adipokines Proteins 0.000 description 4
- 108010076365 Adiponectin Proteins 0.000 description 4
- 102000011690 Adiponectin Human genes 0.000 description 4
- 102100031786 Adiponectin Human genes 0.000 description 4
- 102100029470 Apolipoprotein E Human genes 0.000 description 4
- 101710095339 Apolipoprotein E Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 235000019764 Soybean Meal Nutrition 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000478 adipokine Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000036732 histological change Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000004455 soybean meal Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000011759 adipose tissue development Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150018889 FABP4 gene Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000686909 Homo sapiens Resistin Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- 102100024735 Resistin Human genes 0.000 description 2
- 101150097713 SCD1 gene Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000289527 Cordyline terminalis Species 0.000 description 1
- 235000009091 Cordyline terminalis Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 102000013948 Fatty acid-binding protein 4 Human genes 0.000 description 1
- 108050003772 Fatty acid-binding protein 4 Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 1
- 108010066463 Retinoid X Receptor alpha Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000004490 abdominal subcutaneous fat Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
Description
본 발명은 상기 대두가공 부산물을 유효성분으로 하는 비만 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 유효성분으로 대두의 순물, 대두의 침지수 또는 이들의 혼합물을 함유하는 비만 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating obesity using the soybean processing by-product as an active ingredient, and more particularly to a composition for preventing or treating obesity containing pure soybean, soybean immersion water or a mixture thereof as an active ingredient. It is about.
현대사회는 생활수준의 향상으로 인한 식생활의 서구화와 더불어 식생활 패턴의 변화로 인해 식물성 식품의 섭취량은 점차 감소하는 반면 포화지방산이나 콜레스테롤을 많이 함유하고 있는 동물성 식품의 섭취량이 증가함에 따라 비만이 심각한 사회적 문제로 대두되고 있다(Kim et al., 1993). In modern society, the ingestion of vegetable foods is gradually reduced due to the westernization of diet due to the improvement of living standard, and the change in dietary patterns, while the intake of animal foods containing saturated fatty acid or cholesterol is increasing. It is a problem (Kim et al., 1993).
비만(Obesity)은 에너지 섭취와 소비의 불균형으로 인하여 체지방이 과도하게 축적되어 생기는 일종의 대사성 질환으로(Song et al., 2009), 유전적, 환경적 및 사회적 구조 변화 등과 같은 다양한 원인들이 관여하는 복합적 증후군으로(Grundy, 1998; Albu et al., 1997), 과도한 에너지 섭취로 체내 대사 활동으로 소비되고 남은 영양분이 지방 조직에 중성지방으로 축적되어 발생되며 이러한 지방조직이 필요량 이상으로 과도하게 축적되면 정상적인 생리적 및 생화학적 기능에 영향을 미친다(Huh, 1990). 또한 비만의 정확한 기전을 알려져 있지 않으나 비만도가 높을수록 심혈관 장애 질환 등의 위험도가 높아지는 것으로 알려져 있다. 비만은 그 자체가 갖는 문제점 뿐 아니라, 심혈관계 질환이나 당뇨, 호흡기 질환, 골관절염 같은 질병을 유발할 수 있기 때문에 전 세계적으로 비만에 많은 관심이 모아지고 있다(Antipatis and Gil, 2001). Obesity is a metabolic disorder caused by excessive accumulation of body fat due to an imbalance in energy intake and consumption (Song et al., 2009), which is associated with a variety of causes, including genetic, environmental and social structural changes. As a syndrome (Grundy, 1998; Albu et al., 1997), excessive energy intake causes metabolic activity in the body to be consumed, resulting in accumulation of triglycerides in the adipose tissue. Affects physiological and biochemical functions (Huh, 1990). In addition, the exact mechanism of obesity is not known, the higher the obesity is known to increase the risk of cardiovascular disorders. Obesity has attracted much attention worldwide because obesity can cause diseases such as cardiovascular disease, diabetes, respiratory disease, and osteoarthritis, as well as its own problems (Antipatis and Gil, 2001).
비만은 에너지의 과다 섭취, 운동 부족뿐 아니라 내분비적 요인, 약물 원인, 유전적 요인 등이 복합적으로 작용하므로 비만을 개선하기 위한 방법으로는 식사, 운동, 행동 요법이나 약물 치료 등이 쓰이고 있다. 약물 요법으로는 비만을 일으키는 작용기전에 따라서 식욕 억제효과를 나타내는 리덕틸과 지방의 소화흡수 억제효과를 나타내는 제니칼 등과 같은 약물이 임상에서 사용되고 있다(Kim, 2004). 하지만 이러한 약물은 기름변이나 복부 팽만감, 어지러움, 구갈, 변비, 혈압상승 등과 같은 부작용을 유발할 수 있는 것이 알려지면서(Reddy and Chow, 1998), 보다 안전하고 효력이 강한 천연 기능성 물질의 개발이 요구되고 있어 천연 생리활성물질에 관한 많은 연구가 필요한 실정이다.Obesity is a combination of excessive energy consumption, lack of exercise, as well as endocrine factors, drug causes, genetic factors, etc. As a way to improve obesity, diet, exercise, behavioral therapy or drug treatment is used. In drug therapy, drugs such as reductil, which exhibits an appetite suppressing effect, and Xenical, which suppresses digestion and absorption of fats, are used in clinical practice depending on the mechanism of action of obesity (Kim, 2004). However, as these drugs are known to cause side effects such as oily stools, abdominal bloating, dizziness, dry mouth, constipation and increased blood pressure (Reddy and Chow, 1998), the development of safer and more potent natural functional substances is required. There is a need for a lot of research on natural bioactive substances.
국내의 경우, 다수의 천연물질이 비만 예방에 효과가 있는 건강식품으로 시판되고 있으나 이들 대부분은 과학적인 검증을 거치지 않은 것이 많으며 오히려 건강식품 남용의 원인이 되기도 하여 사회적인 문제가 되고 있다.In Korea, many natural substances are marketed as health foods that are effective in preventing obesity, but most of them are not scientifically verified, and they are often social problems because they cause health food abuse.
한편, 대두 순물, 대두 침지수는 두부 제조 공정 시에 발생되는 부산물로서 현재 순물과 침지수는 두부의 제조과정에서 폐기되고 있다. 일부 대두 순물과 대두 침지수에 대한 항산화 활성(Kim and Lee, 2007)과 기능성 특성(Kim et al., 2006) 및 침지저장액에 따른 두부의 물성 변화(Jang et al., 1995)에 관한 연구가 이루어져 있으나 대두가공 부산물인 순물과 침지수의 생리활성 효능에 관한 연구는 매우 미비한 실정이다. Meanwhile, soybean pure water and soybean immersion water are by-products generated during the tofu production process. Antioxidant Activity (Kim and Lee, 2007), Functional Properties (Kim et al., 2006), and Changes of Soybean Property by Soak Stock (Jang et al., 1995) However, studies on the physiological activity of soybean by-products and soaked water are very poor.
따라서, 식품으로 식이 가능한 천연자원들을 객관적인 검증하여 비만의 치료 및 예방효과를 갖는 천연물질을 개발하고자하는 노력이 시급히 요구된다.Therefore, there is an urgent need for an effort to objectively verify natural foods that can be eaten as foods and to develop natural materials having a therapeutic and preventive effect on obesity.
이에, 본 발명자들은 비만의 치료 및 예방효과를 갖는 천연물질의 개발에 지속적인 연구를 진행하던 중 대두가공 부산물인 대두 순물과 대두 침지수가 고지방 식이에 의한 마우스의 지질대사 개선과 항비만에 대한 우수한 천연 생리활성 효능을 확인하고, 본 발명을 완성하였다.Therefore, the present inventors are continuing to study the development of natural substances having a therapeutic and preventive effect of obesity, soybean by-products and soybean immersion water is a natural high-fat diet for improving lipid metabolism and anti-obesity of the mouse by high-fat diet Confirming the physiological activity efficacy, the present invention was completed.
본 발명의 목적은 인체에 무해하며 고지방 식이에 의한 체내 지방 축적의 감소시킬 수 있는 천연식품 추출물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a natural food extract that is harmless to the human body and can reduce the accumulation of fat in the body by a high fat diet.
또한, 본 발명은 비만의 예방 및 치료효과를 갖는 대두가공 부산물을 제공하는 것을 목적으로 한다.It is also an object of the present invention to provide a soybean processing by-product having a prophylactic and therapeutic effect of obesity.
또한 본 발명은 상기 대두가공 부산물을 유효성분으로 하는 비만 예방 또는 치료용 조성물을 제공하는 것을 목적으로 한다.In another aspect, the present invention is to provide a composition for the prevention or treatment of obesity, the soybean by-products as an active ingredient.
상기 목적을 달성하기 위하여 본 발명은 비만 예방 또는 치료용 조성물을 제공하는 것으로, 보다 상세하게는 대두가공 부산물을 유효성분으로 하는 비만 예방 또는 치료용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for preventing or treating obesity, and more particularly, a composition for preventing or treating obesity, using soybean by-product as an active ingredient.
또한 본 발명은 상기 조성물을 포함하는 건강보조 식품을 제공한다.In another aspect, the present invention provides a dietary supplement comprising the composition.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에 따른 조성물은 대두가공 부산물을 함유하는 것을 특징으로 하며, 보다 상세하게는 고지방 식이에 의한 비만을 예방하고 치료하는 용도인 대두가공 부산물 및 이를 함유하는 비만 예방 또는 치료용 조성물을 제공하는 것을 특징으로 한다.The composition according to the present invention is characterized in that it contains soybean processing by-products, and more particularly, to provide a soybean processing by-product and a composition for preventing or treating obesity containing the same for the purpose of preventing and treating obesity due to a high fat diet. It features.
상기 본 발명의 대두가공 부산물은 대두 침지수(soybean soaking water), 두부 순물(soybean curd whey) 또는 이들의 혼합물인 것을 특징으로 한다.The soybean processing by-product of the present invention is characterized in that the soybean soaking water (soybean soaking water), soybean curd whey or a mixture thereof.
본 명세서에서, 용어 “예방”은 질환 또는 질병을 보유하고 있다고 진단된 적은 없으나, 이러한 질환 또는 질병에 걸리기 쉬운 경향이 있는 동물에서 질환 또는 질병의 발생을 억제하는 것을 의미한다. 본 명세서에서 용어“치료”는 (a) 질환 또는 질병의 발전의 억제; (b) 질환 또는 질병의 경감; 및 (c) 질환 또는 질환의 제거를 의미한다.As used herein, the term "prevention" refers to inhibiting the occurrence of a disease or condition in an animal that has never been diagnosed as having a disease or condition but is prone to such disease or condition. As used herein, the term “treatment” refers to (a) inhibiting the development of a disease or condition; (b) alleviation of the disease or condition; And (c) elimination of the disease or condition.
본 발명은 유효성분으로, 대두가공 부산물을 함유하는, 비만 예방 또는 치료용 조성물을 제공한다.The present invention provides a composition for preventing or treating obesity, containing soybean processing by-products as an active ingredient.
상기 대두가공 부산물은 대두 침지수(soybean soaking water), 두부 순물(soybean curd whey) 또는 이들의 혼합물인 것으로, 보다 바람직하게는 대두 침지수를 이용하는 것을 특징으로 한다.The soybean processing by-products are soybean soaking water, soybean curd whey or a mixture thereof, and more preferably soybean soaking water.
본 발명에 있어서, 상기 두부 순물(soybean curd whey)은 보다 상세하게는 두부 제조 시 발생하는 액상의 순물을 10,000 내지 14,000 rpm으로 원심분리한 후, 여과지를 이용하여 고형분을 제거하여 수득된 상층액, 상기 상층액의 농축물, 또는 상기 농축물을 동결 건조하여 제조한 건조물을 포함한다.In the present invention, the soybean curd whey is more specifically, the supernatant obtained by centrifuging the liquid pure water generated during tofu production at 10,000 to 14,000 rpm, using a filter paper to remove the solids, Concentrate of the supernatant, or dried product prepared by freeze-drying the concentrate.
본 발명에 있어서, 상기 대두 침지수(soybean soaking water)는 대두를 상온의 물에 침지하여 수득되는 것으로, 보다 상세하게는 대두를 열수가열 없이, 10 내지 30℃의 온도의 물에 3 내지 24시간 침지한 후 수득되는 여과물, 상기 여과물의 농축물, 또는 상기 농축물을 동결 건조하여 제조한 건조물을 포함한다. In the present invention, the soybean soaking water is obtained by immersing soybean in water at room temperature, more specifically, soybean soaked in water at a temperature of 10 to 30 ℃ without hydrothermal heating for 3 to 24 hours Filtrate obtained after immersion, concentrate of the filtrate, or dried product prepared by freeze drying the concentrate.
본 발명의 조성물은 상기 대두 침지수(soybean soaking water), 두부 순물(soybean curd whey) 또는 이들의 혼합물인 유효성분을 전체 조성물 중 0.001 내지 30 중량%로 포함하여 제조될 수 있다.The composition of the present invention may be prepared by containing the active ingredient, soybean soaking water, soybean curd whey or a mixture thereof in an amount of 0.001 to 30% by weight of the total composition.
상기 유효성분은 간과 부고환 조직의 지방 변성 및 지방축적 억제; 체내 콜레스테롤의 축적 억제; 중성지방의 축적 억제, 전지방세포의 지방세포로의 분화, 지방세포의 증식; 지방생성의 억제; 아세틸-코에이 카르복실라제(ACC, acetyl-CoA carboxylase)의 활성 억제; 및 AMP 유도 활성화 단백질 키나아제(AMPK, AMP-activated protein kinase)의 활성 증가;로부터 선택되는 1종 이상의 작용을 통하여 비만에 대한 근본적인 원인을 제어하는 것을 특징으로 한다.The active ingredient is fat degeneration and fat accumulation inhibition of liver and epididymal tissue; Inhibition of accumulation of cholesterol in the body; Inhibition of the accumulation of triglycerides, differentiation of fat cells into adipocytes, proliferation of adipocytes; Inhibition of lipogenesis; Inhibition of the activity of acetyl-CoA carboxylase (ACC); And increasing the activity of AMP-induced activated protein kinase (AMPK), characterized in that it controls the underlying cause for obesity through at least one action selected from.
보다 상세하게는 상기 유효성분은 퍼옥시좀 증식인자 활성화 수용체 감마(PPARγ, peroxisome proliferator activated receptor)의 활성을 저해함으로써 항비만 효과를 가지는 것을 특징으로 한다.More specifically, the active ingredient is characterized by having an anti-obesity effect by inhibiting the activity of peroxisome proliferator activated receptor (PPARγ).
본 발명의 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나, 분말제, 과립제, 정제, 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient, according to methods which can be easily carried out by those skilled in the art. It can be prepared by incorporation into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of a powder, granules, tablets, capsules, and may further include a dispersant or stabilizer.
본 발명의 조성물은 건강 보조 식품으로 개발될 수 있다. 상기 건강보조 식품은 드링크제, 캬라멜, 쵸콜릿, 다이어트바 제형, 및 과자류로부터 선택되는 1종 이상인 것으로, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제[타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 드링크제로 제조되는 경우에는 본 발명의 스탄니오칼신 2 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다. 식품에 대한 용이한 접근성을 고려한다면, 본 발명의 식품은 비만의 치료 또는 예방, 및 인지 기능의 개선에 매우 유용하다.The composition of the present invention can be developed as a dietary supplement. The dietary supplement is one or more selected from a drink, caramel, chocolate, diet bar formulation, and confectionary, and includes ingredients commonly added in the manufacture of food, for example, proteins, carbohydrates, fats, nutrients, Seasonings and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when prepared with a drink, in addition to staniocalcin 2 of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, tofu extract, jujube extract, licorice extract, and the like may be further included. Given the easy access to food, the food of the present invention is very useful for the treatment or prevention of obesity, and for improving cognitive function.
본 발명에 따른 조성물은 천연 식품의 추출물을 사용하여 인체에 무해하며, 체내 지방의 축적을 감소시킬 수 있는 효과가 탁월할 뿐 아니라 지방산 산화의 촉진을 억제함으로써 고지방 섭취에 의해 발생되는 비만을 예방 및 치료에 부작용 없이 효과적으로 사용할 수 있으며, 비만에 기인한 대사성 및 심혈관, 뇌혈관 질환, 암과 같은 다양한 질병의 예방에 크게 기여할 수 있는 장점이 있다.The composition according to the present invention is harmless to the human body using extracts of natural foods, has an excellent effect of reducing the accumulation of fat in the body, and also prevents obesity caused by high fat intake by inhibiting the promotion of fatty acid oxidation. It can be effectively used without side effects in the treatment, there is an advantage that can greatly contribute to the prevention of various diseases such as metabolic and cardiovascular, cerebrovascular disease, cancer caused by obesity.
도 1은 본 발명에 따른 대두가공 부산물 섭취 식이군에 대한 간세포의 조직학적 변화를 확인한 결과이고,
(A: 정상 식이군, B: 고지방 식이군, C: 대두 순물 식이군, D: 대두 침지수 식이군)
도 2는 본 발명에 따른 대두가공 부산물 섭취 식이군에 대한 지방세포의 조직학적 변화를 확인한 결과이며,
(A: 정상 식이군, B: 고지방 식이군, C: 대두 순물 식이군, D: 대두 침지수 식이군)
도 3은 본 발명에 따른 대두가공 부산물 섭취 식이군에 대한 아세틸-코에이 카르복실라제(acetyl-CoA carboxylase)의 인산화를 확인한 결과이고,
(ND: 정상 식이군, HFD: 고지방 식이군, H-SCW: 대두 순물 식이군, H-SSW: 대두 침지수 식이군)
도 4는 본 발명에 따른 대두가공 부산물 섭취 식이군에 대한 마우스 복부 지방조직의 분포를 확인한 결과이며,
(A: 정상 식이군, B: 고지방 식이군, C: 대두 순물 식이군, D: 대두 침지수 식이군)
도 5는 본 발명의 대두가공 부산물 처리 농도에 따른 전지방세포의 세포 생존율을 확인한 것이고,
도 6은 본 발명의 대두가공 부산물 처리 농도에 따른 지방세포 내 지방함량을 확인한 것이며,
도 7은 지방세포의 분화 전(A) 및 분화 후(B)의 모습을 현미경을 통해 확인한 결과이고,
도 8은 본 발명의 대두가공 부산물 처리 농도에 따른 전지방세포의 분화능을 확인한 결과이며,
도 9는 본 발명의 대두가공 부산물 처리 농도에 따른 퍼옥시좀 증식인자 활성화 수용체 감마(PPARγ)의 발현을 확인한 결과이고,
도 10은 본 발명의 대두가공 부산물 처리 농도에 따른 지방대사 관계 유전자들의 발현을 RT-PCR로 확인한 결과이며,
도 11은 본 발명의 대두가공 부산물 처리 농도에 따른 지방대사 관계 유전자들의 발현을 ImageQuant program을 이용해 정량화한 결과이고,
(A: APOE, B: adipsin, C: Fabp4, D: Scd1)
도 12는 본 발명의 대두가공 부산물 처리 농도에 따른 아디포카인(adipokine) 관계 유전자들의 발현을 확인한 결과이다.1 is a result confirming the histological changes of hepatocytes for the soybean by-product intake diet group according to the present invention,
(A: normal diet group, B: high fat diet group, C: soybean pure water diet group, D: soybean immersion diet group)
Figure 2 is a result confirming the histological changes of fat cells for the soybean by-product intake diet group according to the present invention,
(A: normal diet group, B: high fat diet group, C: soybean pure water diet group, D: soybean immersion diet group)
Figure 3 is a result confirming the phosphorylation of acetyl-CoA carboxylase (acetyl-CoA carboxylase) for soybean by-product intake diet group according to the present invention,
(ND: normal diet, HFD: high fat diet, H-SCW: soybean pure diet, H-SSW: soybean immersion diet)
Figure 4 is a result confirming the distribution of mouse abdominal adipose tissue for soybean by-product intake diet group according to the present invention,
(A: normal diet group, B: high fat diet group, C: soybean pure water diet group, D: soybean immersion diet group)
5 is a cell survival rate of the cells according to the soybean processing by-product treatment concentration of the present invention,
Figure 6 confirms the fat content in fat cells according to the soybean processing by-product treatment concentration of the present invention,
Figure 7 is a result of confirming the state before and after differentiation (A) and differentiation of fat cells through a microscope,
8 is a result of confirming the differentiation capacity of the cells according to the soybean processing by-product treatment concentration of the present invention,
9 is a result confirming the expression of the peroxysome growth factor activator receptor gamma (PPARγ) according to the soybean processing by-product treatment concentration of the present invention,
10 is a result of confirming the expression of fat metabolism related genes according to the soybean processing by-product treatment concentration of the present invention by RT-PCR,
11 is a result of quantifying the expression of fat metabolism related genes according to the soybean processing by-product treatment concentration of the present invention using an ImageQuant program,
(A: APOE, B: adipsin, C: Fabp4, D: Scd1)
12 shows the results of confirming the expression of adipokine related genes according to the soybean by-product treatment concentration of the present invention.
본 발명은 하기 실시예에 의하여 더욱 구체적으로 설명한다. 그러나, 하기 실시예는 본 발명의 이해를 돕기 위한 것일 뿐, 어떤 의미로든 본 발명의 범위가 이러한 실시예에 의하여 한정되는 것은 아니다.The present invention will be described in more detail with reference to the following examples. However, the following examples are provided to aid understanding of the present invention, and the scope of the present invention is not limited by these examples in any sense.
이때, 사용되는 기술 용어 및 과학 용어에 있어서 다른 정의가 없다면, 이 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 통상적으로 이해하고 있는 의미를 가지며, 하기의 설명 및 첨부 도면에서 본 발명의 요지를 불필요하게 흐릴 수 있는 공지 기능 및 구성에 대한 설명은 생략한다.Hereinafter, the technical and scientific terms used herein will be understood by those skilled in the art without departing from the scope of the present invention. Descriptions of known functions and configurations that may be unnecessarily blurred are omitted.
[제조예] [Manufacturing Example]
(1) 두부 순물(soybean curd whey)(1) soybean curd whey
실험에 사용한 순물 시료는 두부 제조 시 발생하는 액상의 순물을 12,000 rpm으로 원심분리한 후, 여과지(whatman No.1)를 이용하여 고형분을 제거하여 상층액을 수득하고, 수득된 상층액을 농축, 동결 건조하여 건조시료를 사용하였다. 한편, 액상시료는 두부 제조 시 발생하는 액상의 순물을 그대로 시료로 하였다.The pure water sample used in the experiment was centrifuged at 12,000 rpm of the liquid pure water generated in the preparation of tofu, and then the solids were removed using a filter paper (whatman No. 1) to obtain a supernatant, and the obtained supernatant was concentrated, Lyophilization was used to dry samples. On the other hand, the liquid sample was taken as the pure water of the liquid generated when manufacturing tofu as a sample.
(2) 대두 침지수(soybean soaking water)(2) soybean soaking water
대두를 열수가열 없이, 15℃의 물에 8 시간 침지한 후, 여과, 농축, 동결 건조하여 사용하였다. Soybeans were immersed in water at 15 ° C. for 8 hours without hot water, filtered, concentrated, and lyophilized.
[[ 실험예Experimental Example 1] One]
본 실험에서 사용한 3주령 수컷 마우스(C57BL/6)는 (주)샘타코에서 구입하여, 사육실에서 일정한 조건(온도 21.4±0.05℃, 습도 61±1%, 명암은 12시간 주기)에서 사육하였다. 식이는 물(증류수)과 사료[(주)중앙실험동물에서 구입한 Dyets사 사료(AIN-93G Purified Rodent Diet)]를 충분히 섭취하게 하면서 1주일 동안 순치하였다. Three-week-old male mice (C57BL / 6) used in this experiment were purchased from Samtaco Co., Ltd., and were bred under constant conditions (temperature 21.4 ± 0.05 ° C, humidity 61 ± 1%, light and shade for 12 hours) in the breeding room. The diet was incubated for one week with sufficient intake of water (distilled water) and feed (Dyets feed (AIN-93G Purified Rodent Diet) purchased from central experimental animals).
순치 후 실험동물은 각 실험군에 따라 각각 고지방 사료를 섭취시켜(40% Beef Tallow+AIN-76A Diet) 약 7주간 비만 유도 및 각 시료가 비만 유도에 영향을 조사하였다. 식이와 식수는 자유롭게 섭취하도록 하였고, 모든 실험식이는 사육 기간 동안 냉장 보관 하여 실험에 사용하였다. After the treatment, the animals were fed a high-fat diet (40% Beef Tallow + AIN-76A Diet) according to each experimental group. The diet and drinking water were taken freely, and all experimental diets were refrigerated during the breeding period and used in the experiments.
실험군은 총 4개 그룹으로 정상 식이군(Normal diet (fat: 11.7%), ND), 고지방 식이군[High fat diet(fat : 40%), HFD], 10% 대두 순물 식이군[high fat(fat: 40%)+상기 제조예에서 제조한 10% 대두 순물, H-SCW], 10% 대두 침지수 식이군[high fat(fat: 40%)+상기 제조예에서 제조한 10% 대두 침지 후, H-SSW]으로 나누어 약 7주간 하기 표 1과 같이 각기 다른 조성의 사료를 섭이시켰다. 또한 실험기간 동안 체중 변화를 관찰하기 위해서 매일 일정시간에 체중을 측정하고, 사료와 식수의 변화량을 체크하였다. The experimental group consisted of four groups: normal diet (fat: 11.7%), ND, high fat diet (fat: 40%), HFD, and 10% soybean pure diet (high fat). fat: 40%) + 10% soybean pure, H-SCW] prepared in the above preparation, 10% soybean immersion diet group [high fat (fat: 40%) + after 10% soybean immersion prepared in the above preparation , H-SSW] divided the feed of different compositions as shown in Table 1 for about 7 weeks. In addition, the weight was measured at a certain time every day to observe the weight change during the experiment, and the amount of change in feed and drinking water was checked.
본 실험예에서 모든 동물실험 과정은 NIH(National Institutes of Health)의 실험동물관리 규정(Principle of Laboratory Animal Care)과 안동대학교의 실험동물 관리와 사용 지침의 규정에 따라 수행하였다.In this experiment, all animal experiments were performed according to the National Institutes of Health (Principle of Laboratory Animal Care) and Andong National University experimental animal care and use guidelines.
실험 최종일에 실험동물을 약 12시간 절식시킨 후 에테르(ether)로 마취시킨 후, 경동맥에서 혈액을 채취하였다. 혈액은 serum용 튜브에 받아 1600 x g 에서 15분간 원심분리 후 혈청을 얻고, 분석 전까지 -80℃에서 냉동 보관하였다. 혈액 채취 후 실험동물을 개복한 부고환 지방 조직과 간조직을 적출하고 생리식염수에 세척한 후 여과지로 물기를 닦아내었다. 전자저울로 생조직의 중량을 측정하고 분석하기 전까지 -80℃에서 냉동 보관하였다. On the last day of the experiment, the animals were fasted for about 12 hours, anesthetized with ether, and blood was collected from the carotid artery. Blood was collected in serum tubes and centrifuged at 1600 x g for 15 minutes to obtain serum, and frozen at -80 ° C until analysis. After blood collection, the experimental animals were opened and the epididymal adipose tissue and liver tissue were removed, washed with physiological saline, and then wiped dry with filter paper. Electronic tissues were weighed and stored frozen at -80 ° C until analyzed.
(1) 간과 부고환 지방조직에서 지방 조직량과 조직학적 변화 (1) Adipose tissue mass and histological changes in liver and epididymal adipose tissue
대두 순물과 대두 침지수가 고지방 식이에 의한 마우스의 비만에 미치는 영향을 알아보기 위하여 간과 부고환 지방 조직의 중량을 측정하여 비교해보았다.To determine the effect of soybean sprouts and soybean immersion on obesity in mice caused by high fat diet, liver and epididymal adipose tissue were weighed and compared.
지방조직의 중량를 측정하기 위하여 개복 직후 간조직 및 부고환 지방 조직을 적출한 뒤 인산완충용액으로 세척한 다음 여과지로 수분을 제거하고 중량을 측정하여 하기 표 2에 나타내었다. In order to measure the weight of the adipose tissue, liver tissue and epididymal adipose tissue were immediately extracted after laparotomy, washed with phosphate buffer solution, and then water was removed with a filter paper, and the weight thereof was shown in Table 2 below.
상기 표 2에서도 확인할 수 있듯이, 각 실험군 당 간조직의 중량은 고지방 식이군이 정상 식이군에 비하여 83.2% 높게 나타났다. 반면 대두 순물 식이군과 대두 침지수 식이군은 고지방 식이군에 비해 각각 24.8%, 68.3%의 감소되었다. 또한 부고환 지방의 중량을 조사한 결과 고지방 식이군이 정상 식이군에 비해 210% 높게 나타났으며, 대두 순물 식이군과 대두 침지수 식이군은 고지방 식이군에 비해 각각 24.3%, 76.9%로 감소하였다. As can be seen in Table 2, the weight of liver tissue in each experimental group was 83.2% higher in the high fat diet group than the normal diet group. On the other hand, the soybean pure water diet and soybean immersion diet group decreased 24.8% and 68.3%, respectively, compared to the high fat diet group. The weight of epididymal fat was 210% higher in the high fat diet group than in the normal diet group, and the soybean pure diet group and the soybean immersion diet group were reduced to 24.3% and 76.9%, respectively.
또한, 지방조직의 지방세포 크기를 확인하기 위하여 중량 측정이 끝난 지방 조직을 4% 포름알데히드 용액으로 고정하였다. 고정 후 수세와 탈수 과정을 거친 다음 파라핀(paraffin) 용액을 처리하여 파라핀 블록(paraffin block)을 만든 후 4 내지 6 ㎛의 두께로 절편화 하였다. 절편화된 조직은 헤마톡 실린(hematoxylin)과 에오신(eosin)에 이중염색한 후, 광학현미경(Olympus BX50, Japan)하에서 관찰하고, 사진 촬영은 Olympus DP-71을 사용해 각 실험군들의 지방조직을 관찰하였다(Heo etal.,2009;Choietal.,2006).In addition, in order to confirm the fat cell size of the adipose tissue, the gravimetric fat tissue was fixed with 4% formaldehyde solution. After fixing, washing with water and dehydration, and then treated with a paraffin (paraffin) solution to make a paraffin block (section) to a thickness of 4 to 6 ㎛. The sectioned tissue was double-stained with hematoxylin and eosin, and then observed under an optical microscope (Olympus BX50, Japan), and photographed using Olympus DP-71 to observe the adipose tissue of each experimental group. (Heo et al., 2009; Choietal., 2006).
그 결과, 고지방 식이군은 과량의 지방과 콜레스테롤이 정상적으로 체외 배출되지 못하여 간 내의 지방 축적이 유도됨으로서 간이 비대해진 것으로 보이며, 체지방 축적을 대표하는 부고환 지방 조직의 중량을 조사한 결과 고지방 식이로 인해 증가하는 경향을 보였으나 순물과 침지수의 식이로 인하여 지방 축적이 감소되는 것으로 나타났다. 이는 고지방 식이군은 과량의 지방과 콜레스테롤이 정상적으로 체외 배출되지 못하여 간 내의 지방 축적이 유도됨으로서 간과 부고환 지방 조직이 비대해졌으나 대두 순물과 대두 침지수는 고지방 식이로 인한 간 내 지방과 부고환 지방의 축적을 감소시키는 데 효과가 있는 것을 확인한 결과이기도 하다.As a result, in the high fat diet group, excess fat and cholesterol were not normally discharged in vitro, leading to the accumulation of fat in the liver, resulting in hypertrophy.The weight of the epididymal adipose tissue representing body fat accumulation increased due to the high fat diet. The diet of pure water and immersion decreased fat accumulation. In the high fat diet group, excess fat and cholesterol were not normally excreted in vitro, leading to fat accumulation in the liver, resulting in enlargement of liver and epididymal adipose tissue, while soybean pure water and soybean immersion water accumulated liver fat and epididymal fat due to high fat diet. It is also the result of confirming that it is effective in reducing the
특히, 대두 침지수는 고지방 식이로 인한 간과 부고환 지방 조직의 지방 축적을 현저하게 억제시킨 것으로 보아, 고지방 식이에 의한 복부비만억제와 대사성 질환을 예방하는 데에는 순물보다는 침지수가 더 효과적인 생리활성 물질임을 확인할 수 있었다.In particular, soybean immersion significantly inhibited the accumulation of fat in the liver and epididymal adipose tissue due to high fat diets, and it was found that immersion water is more effective than pure water to prevent abdominal obesity and metabolic diseases caused by high fat diet. Could.
(2) 간과 부고환 지방조직에서의 병리조직학적 변화 (2) Pathological changes in liver and epididymal adipose tissue
간은 포도당을 글리코겐으로 합성하여 저장하는 역할을 하는 소화기관으로 동화작용에 의해 생성된 글리코겐은 혈당을 조절하는 용도로 쓰이지만, 지나치게 많아진 경우 지방의 형태로 전환되어 저장되기 때문에 간의 중량 증가 및 조직적 변화를 유발하게 된다(Friedman et al., 1991). 또한 비만은 지방 조직 중량의 증가와 혈중 지방함유량의 증가를 특징으로 하기 때문에 부고환의 지방에 대한 조사는 체중 변화와 비만을 조사하는 데 중요한 지표로서 고지방 식이로 인한 비만 유도 시 부고환 지방의 중량과 크기는 모두 증가하게 된다(Fujioka, 2002). The liver is a digestive system that plays a role in synthesizing and storing glucose as glycogen. Glycogen produced by assimilation is used to control blood sugar, but when it is excessively converted, it is stored in the form of fat. Cause change (Friedman et al., 1991). Also, since obesity is characterized by an increase in adipose tissue weight and an increase in blood fat content, the investigation of fat in the epididymis is an important indicator for examining weight changes and obesity. All increase (Fujioka, 2002).
이러한 측면에서 순물과 침지수가 고지방 식이에 의한 마우스의 간과 부고환 지방의 조직학적 변화에 미치는 영향을 조사하여 본 결과 도 1에서도 확인할 수 있듯이, 정상 식이군의 간 조직은 세포 핵이 대체로 둥글고 중앙에 위치하였으며 간세포 사이의 쿠퍼세포가 전체적으로 고르게 퍼져있는 것을 확인할 수 있었다. 반면 고지방 식이로 비만을 유도한 마우스의 경우 핵 주위에 심한 지방 변성과 공포 현상이 나타났으며 이로 인해 세포질안의 핵이 주변으로 밀려 있었고 정상군에서 관찰되던 쿠퍼세포는 현저히 감소되었다. In this regard, the effects of pure water and immersion on the histological changes of liver and epididymal fat in mice caused by high-fat diets can be seen in FIG. 1. As shown in FIG. 1, the liver nucleus of the normal diet group is generally round and centered. Cooper cells between the hepatocytes were found to be evenly spread throughout. On the other hand, high fat diet-induced obesity resulted in severe fat degeneration and phobia around the nucleus, which caused the nucleus in the cytoplasm to be pushed to the periphery and significantly reduced Cooper cells observed in the normal group.
이에 반해 대두 순물 식이군은 정상 식이군에 비해 세포 내 지방 축적으로 인하여 간세포가 비대화되어 있었으나 고지방 식이군과 같은 간세포 체적의 지방공포 현상은 뚜렷하지 않았고, 대두 침지수 식이군의 경우 간 조직은 일부의 지방공포만이 확인될 뿐 대다수의 간세포와 쿠퍼세포가 정상 간세포와 유사한 것으로 나타나 고지방 식이군과 같은 심각한 간 조직의 이상현상은 나타나지 않는 것을 확인할 수 있었다. In contrast, the soybean pure diet group had hepatocellular hypertrophy due to intracellular fat accumulation compared to the normal diet group, but the fat phobia of the hepatocyte volume such as the high-fat diet group was not obvious. Only the fat vesicles of were identified, and the majority of hepatocytes and Cooper cells were similar to normal hepatocytes, indicating no serious abnormalities of liver tissue such as high fat diet group.
또한 대두 순물과 대두 침지수가 흰색지방인 부고환지방의 형태조직학적 변화에 미치는 영향을 살펴본 결과 도 2에서도 확인할 수 있듯이, 정상 식이군에 비해 고지방 식이군은 지방의 축적으로 인하여 지방 세포의 크기가 매우 커진 것을 확인할 수 있었다.In addition, as a result of examining the effect of soybean pure water and soybean immersion on morphological changes of the epididymal fat, which is white fat, as shown in FIG. 2, the high fat diet group has a very large fat cell size due to the accumulation of fat. It was confirmed that the larger.
반면 대두 순물 식이군과 대두 침지수 식이군은 고지방 식이군에 비하여 지방세포가 작아져 있었는데, 특히 대두 침지수 식이군의 경우 지방세포의 수는 정상 식이군에 비해 다소 많았으나 세포의 크기는 정상 지방세포와 거의 유사한 것을 확인할 수 있었다.On the other hand, the soybean pure and soybean submerged diet groups had smaller fat cells than the high-fat diet group. Especially, the soybean submerged diet group had more fat cells than normal diet group, but the cell size was normal. Almost similar to the fat cells were confirmed.
상기의 결과는 최근 연구에서 Moon 등(2003)은 한약재로 구성된 천연 소재 조성물이 부고환 지방 조직량의 감소와 지방세포 크기를 감소시켜 항비만에 효과가 있다고 한 바 있으며, Yuan 등(2009)은 간과 부고환 지방의 축적을 감소시키는 효과가 있다고 보고된 바와 같이, 상기 실시예의 대두 순물 및 대두의 침지수가 고지방 식이로 인한 간과 부고환 조직의 지방 변성을 억제하는 데에 효과적임을 확인한 결과이며, 나아가 항비만 효과가 있음을 확인한 결과이기도 하다.In the recent study, Moon et al. (2003) found that natural ingredients composed of herbal medicines are effective in anti-obesity by reducing epididymal adipose tissue volume and adipocyte size, and Yuan et al. (2009). As reported to have an effect of reducing the accumulation of epididymal fat, soybean pure water and soybean immersion of the embodiment was found to be effective in suppressing the fat degeneration of liver and epididymal tissue due to high-fat diet, further anti-obesity effect It is also the result of confirming that there is.
(3) 혈액 성분의 생화학분석(3) biochemical analysis of blood components
비만에서는 지방 대사와 당대사의 비정상적 흐름으로 인한 다양한 이상지혈증이 흔히 동반되고, 기존의 연구에 따르면 비만을 식이로 유도한 동물의 경우 중성지방과 콜레스테롤, 그리고 혈당 수치 증가에 대한 결과가 보고된 바 있다(Lee et al., 2006). Obesity is often accompanied by various dyslipidemia due to abnormal flow of fat metabolism and glucose metabolism, and previous studies have reported results of elevated triglycerides, cholesterol and blood glucose levels in obese diet-induced animals. (Lee et al., 2006).
또한 혈장의 GOT와 GPT 효소의 활성도 변화는 간세포의 변성과 괴사가 진행되어 아미노기 전이효소(transaminase)가 혈중 유리되어 높아짐에 따라서 간 조직 손상의 지표가 된다. In addition, changes in the activity of GOT and GPT enzymes in plasma are an indicator of liver tissue damage as hepatic cell degeneration and necrosis progress, resulting in the release of aminotransaminase into the blood.
본 실험에서는 채혈한 혈액은 3,000 rpm에서 10분간 원심분리한 혈장을 분석에 사용하였다. 분리된 혈장은 아미노산 전이효소(GOT, GPT), 총콜레스테롤(total cholesterol), 고밀도 지질단백질(high density lipoprotein), 저밀도 지질단백질(low density lipoprotein), 총 지질(total lipid) 및 중성지방(triglyceride) 함량의 조사를 위해 혈액분석기(Hitachi 7600)에서 분석하였다. In this experiment, the collected blood was used for analysis of plasma centrifuged at 3,000 rpm for 10 minutes. Isolated plasma contains amino acid transferases (GOT, GPT), total cholesterol, high density lipoproteins, low density lipoproteins, total lipids and triglycerides. The content was analyzed in a blood analyzer (Hitachi 7600).
그 결과 상기 표 3에서도 확인할 수 있듯이, 혈청 중 GOT 활성은 정상 식이군과 각 실험군을 비교하였을 때에 고지방 식이군은 27.8%, 대두 순물 식이군은 57.1%, 대두 침지수 식이군은 20.6% 정도 증가율을 보였으며, GPT 활성은 정상 식이군에 비해 고지방 식이군과 대두 순물 식이군이 모두 증가하였으나 대두 침지수 식이군의 경우 정상 식이군과 유사한 수치를 나타내었다. As a result, as can be seen in Table 3, the GOT activity in serum was 27.8% in the high-fat diet group, 57.1% in the soybean meal group, and 20.6% in the soybean immersion diet group when compared to the normal diet group and each experimental group. GPT activity was increased in both high fat and soybean meal groups compared to normal diet group, but the soybean immersion diet group showed similar values to normal diet group.
이와 더불어 혈청 중 총 콜레스테롤 수치는 정상 식이군에 비하여 고지방 식이군이 93.6%, 대두 순물 식이군이 71.2%, 대두 침지수 식이군이 13.2%로 나타났고, 특히 중성지방 함량은 고지방 식이군이 정상 식이군에 비해 252.7% 증가하여 매우 큰 폭의 수치변화를 보였으며, 대두 순물 식이군이 247.9%, 대두 침지수 식이군이 82.8%로 나타나 대두 침지수 식이군이 고지방 식이로 인한 체내 콜레스테롤과 중성 지방의 증가율을 감소시키는데 효과적으로 작용하는 것을 확인할 수 있었다. 또한 HDL-콜레스테롤 수치는 정상 식이군에 비해 고지방 식이군이 가장 높게 나타났으며, LDL-콜레스테롤 수치는 대두 침지수 식이군이 고지방 식이군과 대두 순물 식이군에 비하여 가장 낮은 감소폭을 보였다. Serum total cholesterol levels were 93.6% in the high fat diet group, 71.2% in the soybean pure water group, and 13.2% in the soybean immersion diet group, compared to the normal diet group. Soybean immersion diet group showed 247.9% and soybean immersion diet group and 82.8% of soybean immersion diet group. It was confirmed that it works effectively to reduce the increase rate of fat. In addition, HDL-cholesterol levels were higher in the high fat diet group than in the normal diet group, and LDL-cholesterol levels were the lowest in the soybean immersion diet group compared to the high fat diet group and the soybean pure diet group.
혈중 지질 함량의 감소는 관상심혈관계 질환 위험을 감소시킨다는 여러 연구 결과(Park et al., 2005; Wat et al., 2009; Davignon and Cohn, 1996)에 근거하여 상기 실시예의 두부 부산물 중 대두 침지수는 대두 순물에 비해 비만에 의해 유발되는 심혈관계의 위험성을 줄여주는 데 효과적임을 확인한 결과이기도 하다.Soybean immersion in the tofu by-products of the above examples was based on a number of studies (Park et al., 2005; Wat et al., 2009; Davignon and Cohn, 1996) that reducing blood lipid content reduces the risk of coronary heart disease. It is also confirmed that it is effective in reducing the cardiovascular risk caused by obesity compared to soybean pure water.
(4) 비만 표적 단백질의 인산화비(4) phosphorylation ratio of obesity target protein
본 실험에서는 비만의 표적 단백질인 AMPK와 ACC의 활성을 알아보고자 간조직에서 p-AMPK와 p-ACC의 발현을 조사하였다. In this experiment, we investigated the expression of p-AMPK and p-ACC in liver tissues to determine the activity of AMPK and ACC, the target proteins of obesity.
간 조직에서 phospho-AMPK와 phospho-ACC는 웨스턴 블럿(western blot)으로 확인하였다. 간 조직을 lysis buffer(50 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.25% sucrose, 0.4 mg/ml digonin and 1.5 mM PMSF)를 이용하여 균질화 시켰으며, 단백질 정량은 Bio-Rad assay reagent(Bio-Rad, USA)를 이용하여 측정하였다. 간에서 추출한 단백질 40 μg을 전기영동한 후 1차 antibody(p-AMPK-alpha, p-Acetyl-CoA)(Cell signaling Technology, Beverly, USA)를 처리하였고, 2차 antibody(anti-rabbit IgG-HRP)(Santa cruz biotechnology, Santa Cruz, USA)를 처리하여 AMPK와 ACC의 인산화비를 확인하였다.In liver tissues, phospho-AMPK and phospho-ACC were identified by western blot. Liver tissue was homogenized using lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.25% sucrose, 0.4 mg / ml digonin and 1.5 mM PMSF), and protein quantification was performed using Bio-Rad assay reagent (Bio- Rad, USA). 40 μg of protein extracted from liver was electrophoresed and treated with primary antibodies (p-AMPK-alpha, p-Acetyl-CoA) (Cell signaling Technology, Beverly, USA) and secondary antibodies (anti-rabbit IgG-HRP). ) (Santa cruz biotechnology, Santa Cruz, USA) to determine the phosphorylation ratio of AMPK and ACC.
도 3에서도 확인할 수 있듯이 정상 식이군의 p-ACC의 발현에 대해 상대적인 실험군의 인산화비를 조사한 결과, 고지방 식이군의 p-ACC는 23.0%로 나타난 데 반해 대두 순물 식이군은 83.6%, 대두 침지수 식이군은 164.2%로 조사되었다.As can be seen in Figure 3, the result of examining the phosphorylation ratio of the experimental group relative to the expression of p-ACC of the normal diet group, the p-ACC of the high-fat diet group was 23.0%, whereas the soybean pure water diet group 83.6%, soybean saliva The index diet group was 164.2%.
상기의 결과로부터 대두 순물과 대두 침지수는 고지방 식이에 비해 ACC의 인산화에 효과적으로 작용하는 것을 확인할 수 있었으며 특히, 대두 침지수의 경우 ACC의 인산화비가 매우 높기 때문에 metabolic sensor에 해당하는 단백질의 활성화와 지방산 산화 촉진을 억제함으로써 항비만 효과가 매우 높은 것을 확인할 수 있었다. From the above results, it was confirmed that soybean pure water and soybean immersion water acted more effectively on the phosphorylation of ACC than high fat diet. Especially, soybean immersion water has a high phosphorylation ratio of ACC. It was confirmed that the anti-obesity effect was very high by inhibiting the promotion of oxidation.
(5) 복부의 지방조직 분포(5) distribution of adipose tissue
12주령의 수컷 C57BL/6 마우스의 복부 지방 부피를 측정하기 위해 생체 내 미세단층촬영 시스템(In-vivo Micro-CT, Skyscan 1076, SKYSCAN N.V., Belgium)을 이용하여 등뼈(lumbar vertebrae) 2번부터 5번(L2~L5)까지 촬영하였다. 촬영 시 마우스의 마취를 위해 케타민(Ketamine, Huons, 1.5 ml/kg)과 자일라진(Xylazine, Bayer, 0.5 ml/kg)을 사용하였다. 복부 지방 영상의 획득을 위하여 생체 내 미세단층촬영 시스템의 복셀 크기를 35 , 필터는 알루미늄 1.0 mm, 노출시간은 790 ms, 전압은 100 kV, 전류는 100 , 회전각은 1.2 °(deg)로 설정하였다.To determine the abdominal fat volume of 12-week-old male C57BL / 6 mice, using in vivo micro-CT system (In-vivo Micro-CT, Skyscan 1076, SKYSCAN NV, Belgium) Pictures were taken up to (L2 to L5). Ketamine (Ketamine, Huons, 1.5 ml / kg) and xylazine (Xylazine, Bayer, 0.5 ml / kg) were used for anesthesia of the mouse. To obtain abdominal fat imaging, the voxel size of the in vivo microtomography system was set to 35, the filter was 1.0 mm aluminum, the exposure time was 790 ms, the voltage was 100 kV, the current was 100, and the rotation angle was 1.2 ° (deg). It was.
상기 생체 내 미세단층촬영 시스템 촬영을 이용하여 획득한 영상으로부터 Mimics 13.0(materialise N.V., Belgium) 프로그램을 이용하여, 수컷 C57BL/6 마우스 복부 내부의 각 조직들에 해당되는 그레이 값(gray value)을 구하였다. 경계치 기법(threshold method)을 이용하여 측정된 각 조직들의 그레이 값을 기준으로 영상 내에서 등뼈(lumbar vertebral), 체지방 조직(lean tissue), 지방(adipose tissue), 피부(skin)로 각 영역을 구분하였고, 추출한 복부 지방 조직을 3차원 구조로 재구성하고 이로부터 부피를 측정하였다. 측정된 각 개체의 체중량과 복부 전체 지방 부피 및 복부 피하 지방 부피, 복부 내장 지방 부피를 하기 표4에 나타냈다.Gray values corresponding to the tissues in the abdomen of male C57BL / 6 mice are calculated using the Mimics 13.0 (materialize NV, Belgium) program from the images obtained using the in vivo microtomography system. It was. Based on the gray values of the tissues measured using the threshold method, each region is identified by the spine (lumbar vertebral), the lean tissue, the adipose tissue, and the skin in the image. The abdominal adipose tissue extracted was reconstituted into a three-dimensional structure and the volume was measured therefrom. The body weight, total abdominal fat volume, abdominal subcutaneous fat volume and abdominal visceral fat volume of each subject measured are shown in Table 4 below.
상기 표 4 및 도 4에서도 확인할 수 있듯이 마우스의 복부 지방 조직 분포를 생체 내 미세단층 촬영 시스템을 통해 확인해본 결과, 정상 식이군에 비해 고지방 식이군은 상당량의 피하지방과 내장지방이 복부에 높은 면적을 차지하는 것으로 확인되었다. 그러나 10% 대두 순물 식이군은 고지방 식이군보다 더 복부지방이 많이 분포하였으며 10% 대두 침지수 식이군의 경우 대두 순물 섭이군과 고지방 섭이군에 비해 약 1.7 내지 2.7배로 감소됨을 확인할 수 있었다. As shown in Table 4 and FIG. 4, the distribution of abdominal adipose tissue in the mouse was confirmed through an in vivo microtomography system. It was confirmed to occupy. However, the 10% soybean meal group was found to have more abdominal fat distribution than the high-fat diet group, and the 10% soybean immersion diet group decreased by about 1.7 to 2.7 times as compared to the soybean pure and high-fat diet groups.
또한 각 실험군에 따른 체중량과 복부지방을 비교하여 보았을 때 체중량은 고지방 식이군이 40.5±0.5 g으로 가장 높게 나타났으나 내장지방과 피하지방의 부피는 대두 순물 식이군의 총 복부지방의 부피가 4205.7±511.2 ㎣으로 가장 높은 수치를 나타내었다. 반면 대두 침지수 식이군은 고지방 식이군과 대두 순물 식이군에 비하여 복부지방의 부피가 큰 폭으로 감소된 것으로 나타났으며 특히, 피하지방의 부피는 502.0±48.5 ㎣로, 정상 식이군의 431.8±129.7 ㎣과 유사한 수치를 보였다. In addition, when comparing the body weight and abdominal fat of each experimental group, the body weight was highest in the high fat diet group (40.5 ± 0.5 g), but the volume of visceral fat and subcutaneous fat was the total volume of abdominal fat in the soybean pure diet group. The highest value was 4205.7 ± 511.2 수치. On the other hand, the soybean submerged diet group showed a significant decrease in the volume of abdominal fat compared to the high-fat diet and the soybean meal diet. Especially, the subcutaneous fat volume was 502.0 ± 48.5 ㎣ and 431.8 ± in the normal diet group. The figure was similar to 129.7 kPa.
상기의 결과로부터 대두 순물 식이군에 비해 대두 침지수 식이군은 고지방 식이로 인한 복부 지방의 축적을 억제하는 데 효과적인 것임을 확인할 수 있었다.From the above results, it was confirmed that the soybean immersion diet group was more effective in suppressing the accumulation of abdominal fat due to the high fat diet than the soybean pure diet group.
[[ 실험예Experimental Example 2] 2]
(1) (One) 대두가공Soybean Processing 부산물 처리농도에 따른 By concentration of by-product treatment 전지방세포의Cell-like 세포생존율 Cell survival rate
실험에 사용한 3T3-L1 pre-adipocyte cell(전지방세포)은 American Type Culture Collection(ATCC) 로부터 구입하여 사용하였으며, Dulbecco's modified Eagle's medium (DMEM, Gibco Inc., USA) 배지에 10% fetal bovine serum과 1% antibiotics-antimycotic을 첨가하여 5% CO2가 존재하는 37℃ 세포 배양기에서 2~3일에 한 번씩 계대 배양하면서 실험에 사용하였다. The 3T3-L1 pre-adipocyte cells used in the experiment were purchased from the American Type Culture Collection (ATCC) and used in Dulbecco's modified Eagle's medium (DMEM, Gibco Inc., USA) medium with 10% fetal bovine serum. 1% antibiotics-antimycotic was added and used in the experiment while subcultured every 2 to 3 days in a 37 ℃ cell incubator containing 5% CO 2 .
대두부산물 처리에 의한 농도 의존적 세포생존율은 MTT assay로 측정하였다. 배양된 3T3-L1 전지방세포를 96 well plate에 5×103 cells/well 가 되도록 분주하고, 24시간 배양 후 상등액을 제거하고 배지와 함께 대두부산물 추출시료를 10 ppm, 25 ppm, 100 ppm 농도로 처리하였다. Concentration dependent cell viability by soybean by-product treatment was measured by MTT assay. Incubate the cultured 3T3-L1 cells in a 96 well plate at 5 × 10 3 cells / well, remove the supernatant after incubation for 24 hours, and extract soybean by-products with 10 ppm, 25 ppm, 100 ppm concentration. Treated with.
상기 대두부산물을 농도 별로 처리하고 24시간을 배양한 후 MTT 시약(5 mg/ml)을 well 당 10 ㎕첨가하고 3시간 동안 추가 배양하였다. 그 후 상등액을 제거하고 DMSO 150 ㎕를 각 well에 분주하여 30분 교반한 뒤 microplate reader(Infinite200, Tecan Trading AG, Switzerland)를 이용하여 570 nm에서 흡광도를 측정하였다. 이 흡광도는 MTT가 세포에 의해서 환원된 양을 나타내며, 각 well에 생존한 세포수와 비례한다. The soybean by-product was treated by concentration and incubated for 24 hours, 10 μl of MTT reagent (5 mg / ml) was added per well, and further cultured for 3 hours. Then, the supernatant was removed, and 150 μl of DMSO was dispensed into each well, stirred for 30 minutes, and the absorbance was measured at 570 nm using a microplate reader (Infinite200, Tecan Trading AG, Switzerland). This absorbance represents the amount of MTT reduced by cells and is proportional to the number of cells that survived each well.
세포 생존도(%) = (시료처리군의 흡광도/ 대조군의 흡광도) × 100 Cell viability (%) = (absorbance of sample treated / absorbance of control) × 100
그 결과 도 5에서도 확인할 수 있듯이 대두 침지수는 고농도인 100 ppm농도 처리시에 95% 이상의 세포 생존율을 보이는 것을 확인할 수 있었으며, 대두 순물 처리시에는 10 ppm에서 95.21%, 25 ppm에서 92.12%, 100 ppm에서 88.65%의 세포 생존율(P<0.05)을 보여 고농도의 대두가공 부산물을 처리시에 세포 생존율이 일부 감소하는 것을 확인할 수 있었다. As a result, as can be seen in Figure 5, soybean immersion water showed a cell viability of 95% or more when treated with a high concentration of 100 ppm concentration, 95.21% at 10 ppm, 92.12% at 25 ppm when processing soybean pure water. Cell viability (P <0.05) of 88.65% was shown at ppm, indicating that cell viability was partially reduced when high soybean by-products were treated.
(2)지방 분화 억제 효능에 미치는 영향(2) Effect on the effect of inhibiting fat differentiation
3T3-L1 adipocyte cell(지방세포)의 분화 억제 효능에 미치는 영향을 분석하기 위하여 배양된 세포에 분화유도물질과 함께 대두 침지수 및 대두 순물을 각각 10 ppm, 25 ppm, 100 ppm의 농도로 처리하였다. 분화유도과정이 끝난 후 세포를 Oil Red O 염색하여 현미경으로 관찰한 후 지방함량을 정량하였다. 분화유도물질을 처리하지 않은 세포와 분화유도물질을 처리한 세포를 대조군으로 하였다.In order to analyze the effect on the differentiation inhibitory effect of 3T3-L1 adipocyte cells (cultured cells), soybean immersion water and soybean pure water were treated with differentiation-inducing substances at concentrations of 10 ppm, 25 ppm and 100 ppm, respectively. . After the differentiation induction process, the cells were observed under a microscope by Oil Red O staining and fat content was quantified. Cells not treated with differentiation-inducing substances and cells treated with differentiation-inducing substances were used as controls.
그 결과 도 6에서도 확인할 수 있듯이, 분화유도물질을 처리한 세포와 비교하여 대두 순물 추출물을 처리한 군은 10 ppm에서 94.42%, 25 ppm에서 87.09%, 100 ppm에서 79.14%로 나타나 처리 농도가 증가함에 따라 지방세포 내 지방함량이 유의성 있게 감소되는 것을 확인할 수 있었다. As a result, as can be seen in Figure 6, compared with the cells treated with differentiation-inducing substance, the group treated with soybean pure water extract showed 94.42% at 10 ppm, 87.09% at 25 ppm, and 79.14% at 100 ppm, increasing the treatment concentration. As a result, it was confirmed that fat content in adipocytes was significantly decreased.
또한, Oil Red O 염색 후 현미경 관찰 시에도 도 8에서 확인할 수 있듯이, 대두 순물 및 대두 침지수의 농도가 증가함에 따라 염색된 지방함량이 감소함을 확인할 수 있었다.In addition, even when observed under the microscope after Oil Red O staining, it can be seen that as the concentration of soybean pure water and soybean immersion water increased, the dyed fat content decreased.
상기의 결과로부터 대두 순물의 경우 처리농도가 증가할수록 지방세포 분화 억제 효능이 나타남을 확인하였으며, 대두 침지수의 경우는 10 ppm의 저농도 처리시에도 85.54%의 지방세포 분화 억제 효능이 나타남을 확인할 수 있었고, 이는 대두가공 부산물은 전지방세포가 지방세포로 분화하여 지방세포를 형성하는 것을 억제하는 효과가 있음을 확인한 결과이기도 하다. From the above results, it was confirmed that the soybean pure water showed an effect of inhibiting adipocyte differentiation as the concentration increased, and soybean immersion water showed 85.54% of adipocyte differentiation inhibitory effect even at a low concentration of 10 ppm. This is also the result of confirming that soybean processing by-products have an effect of inhibiting the differentiation of fat cells into fat cells to form fat cells.
[[ 실험예Experimental Example 3] 3]
(1) 분화유도 최종 전사 인자 (1) Differentiation-induced final transcription factor PPARPPAR γ의 발현에 미치는 영향 Effect on the expression of γ
3T3-L1 adipocyte cell(지방세포)의 분화유도에 연관된 유전자의 발현에 미치는 영향을 알아보기 위하여 분화 유도 되어진 대조군과 각각 10 ppm, 25 ppm 및 100 ppm의 대두 순물 및 대두 침지수를 처리한 후 분화유도 되어진 실험군을 비교하였다. To investigate the effects on the expression of genes involved in differentiation induction of 3T3-L1 adipocyte cells, differentiation-induced control, 10 ppm, 25 ppm and 100 ppm soybean sprouts and soybean immersion water, respectively, The induced experimental groups were compared.
전지방세포는 적당한 분화 자극과 지방세포형성 유도 조절자의 발현에 의해 최종 전사인자인 PPARγ의 발현을 유도하는 것으로 알려져 있다. 퍼옥시좀 증식인자 활성화 수용체 감마(PPARγ, peroxisome proliferator activated receptor)는 nuclear hormone receptor superfamily에 속하며, PPAR family member로는 PPARα, PPARγ, PPARζ가 알려져 있다. 이들 PPAR 전사인자들은 Retinoid X receptor α와 heterodimer를 이루어 표적 유전자의 PPRE(peroxisome proliferator response element)를 인지하고, 지방 형성에 관련된 지방세포분화 관련 유전자의 발현을 조절한다. 따라서 이를 확인하기 위하여 분화 유도 및 대두부산물의 처리에 따른 지방세포형성의 최종 전사인자인 PPARγ의 발현을 확인하였다. Cells are known to induce the expression of the final transcription factor, PPARγ, by appropriate differentiation stimulation and expression of adipocyte induction regulators. The peroxisome proliferator activated receptor (PPARγ) belongs to the nuclear hormone receptor superfamily, and PPAR family, PPARα, PPARγ, and PPARζ are known. These PPAR transcription factors form heterodimers with Retinoid X receptor α to recognize the peroxisome proliferator response element (PPRE) of target genes and to regulate the expression of adipose cell differentiation-related genes involved in fat formation. Therefore, in order to confirm this, the expression of PPARγ, which is the final transcription factor of adipocyte formation according to differentiation induction and soybean byproduct treatment, was confirmed.
우선, TRIzol (Gibco Inc., USA)을 이용하여 total RNA를 추출한 후 Total RNA Clean up kit(Ambion, USA) 를 사용하여 정제하였다. 정제된 RNA를 template로 SuperScript™ kit(Invitrogen, USA)를 이용하여 single stranded cDNA를 제조하였다. 지방세포분화와 관련된 유전자들을 특이적으로 증폭하기 위해 하기 표 5에 기재된 프라이머를 제작하였으며, 각 유전자의 발현 정도를 GAPDH 유전자의 발현과 비교하여 확인하였다. 유전자의 발현정도는 전기영동 후 ImageQuant 5.2 (GE Healthcare, USA) 프로그램을 이용하여 분석하였다.First, total RNA was extracted using TRIzol (Gibco Inc., USA), and then purified using Total RNA Clean up kit (Ambion, USA). Single stranded cDNA was prepared using the SuperScript ™ kit (Invitrogen, USA) as a template for purified RNA. In order to specifically amplify genes related to adipocyte differentiation, primers described in Table 5 were prepared, and the expression level of each gene was compared with that of the GAPDH gene. Gene expression was analyzed using ImageQuant 5.2 (GE Healthcare, USA) program after electrophoresis.
도 9에서도 확인할 수 있듯이 대두 순물 및 대두 침지수를 처리한 처리구에 대한 PPARγ mRNA발현 양상을 확인할 결과, 지방세포의 분화가 유도된 대조군과 비교하여 대두 순물 및 대두 침지수를 처리한 처리구에서는 PPARγ의 mRNA발현이 감소하는 것을 확인할 수 있었다. As can be seen in Figure 9 as a result of confirming the PPARγ mRNA expression pattern for the treatment group treated with soybean sprout and soybean immersion water, compared to the control group induced the differentiation of adipocytes, the treatment group treated with soybean sprout and soybean immersion water mRNA expression was reduced.
대두 침지수 처리시 모든 처리 농도에서 50% 미만의 발현 감소를 보였으나 일부 농도 비의존적인 현상이 확인되었다. 또한 대두 순물의 경우 처리 농도가 증가함에 따라 PPARγ의 발현이 농도 의존적으로 감소하여 Oil Red O 염색을 통한 세포관찰 결과와 일치하는 것을 확인할 수 있었다. Soybean immersion treatment showed less than 50% reduction in all treatment concentrations, but some concentration-independent phenomena were observed. In addition, in the case of soybean sprouts, the concentration of PPARγ decreased in concentration-dependent manner as the treatment concentration was increased, which was in agreement with the cell observation results through Oil Red O staining.
상기의 결과로부터 대두 순물 및 대두 침지수의 지방 세포 분화 억제는 PPARγ 의 발현의 억제를 통하여 이루어지는 것을 확인할 수 있었다.From the above results, it was confirmed that the inhibition of adipocyte differentiation of soybean sprouts and soybean immersion water was achieved by suppressing the expression of PPARγ.
(2) 지방대사에 대한 대두가공 부산물의 효과(2) Effect of Soybean Processing By-Products on Local Metabolism
지방세포의 분화 유도 과정이 진행되면 전사 조절 인자인 PPARγ의 조절에 의해 지방대사 관련 유전자의 발현이 증가한다. PPARγ의 발현이 증가하면 체내 당의 흡수가 증가되고 지방세포의 분화를 유발하게 되는 것으로 알려져 있다. 또 지방세포의 분화 과정에서 지방 대사에 관여하는 apolipoprotein E(APOE), fatty acid binding protein 4(Fabp 4), adipsin 및 stearoyl-coenzyme A desaturase 1 (Scd 1)은 PPARγ 등의 전사조절인자에 의해 조절되는 것으로 알려져 있어, 본 실험에서는 대두 순물 및 대두 침지수의 지방세포 분화 억제를 확인하기 위하여 이들 유전자의 발현 정도를 분석하였다.As the process of inducing differentiation of adipocytes progresses, expression of adipose metabolism-related genes is increased by the regulation of PPARγ, a transcriptional regulator. Increased expression of PPARγ is known to increase the absorption of sugar in the body and cause differentiation of adipocytes. In addition, apolipoprotein E (APOE), fatty acid binding protein 4 (Fabp 4), adipsin and stearoyl-coenzyme A desaturase 1 (Scd 1), which are involved in fat metabolism, are regulated by transcriptional regulators such as PPARγ. In this experiment, the expression level of these genes was analyzed to confirm the inhibition of adipocyte differentiation of soybean sprouts and soybean immersion water.
그 결과, 도 10 및 도 11에서도 확인할 수 있듯이 APOE의 경우 대조군과 비교하여 대두 순물과 대두 침지수 처리시에는 30 내지 40% 미만으로 발현이 감소하는 것을 확인할 수 있었다. Scd1유전자의 발현은 분화 유도시 미분화에 비해 발현이 증가하나, 대두 순물과 대두 침지수를 처리한 후 대조군과 비교하여 처리농도에 따라 각각 50 내지 85%의 유전자 발현정도를 확인할 수 있었다. As a result, as can be seen in Figures 10 and 11 it was confirmed that the expression of APOE is reduced to less than 30 to 40% during soybean pure water and soybean immersion treatment compared to the control. Expression of Scd1 gene was increased compared to undifferentiated at induction of differentiation, but after treatment with soybean pure water and soybean immersion water, 50 to 85% of gene expression was confirmed according to the treatment concentration, respectively.
반면 Fabp 4의 mRNA 발현은 대조군과 비교하여 대두 순물과 대두 침지수를 처리하였을 때 유전자 발현의 큰 변화가 없음을 확인하였다. 또한 adipsin은 중성지방 아실화(acylation)를 자극하여 complement peptide를 촉진하는 세린 프로테아제(serine protease)로서 배양지방세포에서 주로 확인되며, 분화 유도 과정에서 에너지 저장 신호와 관련하여 발현이 유도되는 것으로 알려져 있다. 대두 순물과 대두 침지수을 처리하였을 때 지방분화세포에서 adipsin의 발현은 전체적으로 농도 의존적으로 억제되는 것을 확인할 수 있었으며 특히, 대두 순물을 10 ppm 농도 처리 시 그 발현량은 지방세포 분화 대조군에 비해 50% 미만으로 감소하였으며. 대두 침지수를 처리하였을 때 농도 의존적으로 adipsin의 발현이 100 ppm 농도에서 각각 45%, 28% 미만으로 감소하였다. On the other hand, Fabp 4 mRNA expression did not change significantly when the soybean sprouts and soybean immersion treatment compared to the control group. Adipsin is a serine protease that promotes complement peptides by stimulating triglyceride acylation, which is mainly found in cultured fat cells, and is known to induce expression in relation to energy storage signals during differentiation induction. . When soybean sprouts and soybean immersions were treated, adipsin expression was suppressed as a whole in adipose-derived cells. In particular, when 10 ppm of soybeans were treated, the expression level was less than 50% compared to the adipocyte differentiation control group. Decreased to. In soybean immersion treatment, adipsin expression was reduced to 45% and less than 28% at 100 ppm concentration, respectively.
지방대사 관련 유전자 중 일부 유전자들의 mRNA 발현을 억제하는 상기의 결과는 대두 순물 및 대두 침지수가 지방대사 과정을 조절하여 지방세포의 분화를 조절함을 확인한 결과이기도 하다. The above result of suppressing mRNA expression of some genes of fat metabolism-related genes is also a result of confirming that soybean pure water and soybean immersion regulate fat process by controlling fat metabolism process.
(3) 아디포카인에 대한 대두가공 부산물의 효과(3) Effect of Soybean Processing By-Products on Adipocaine
지방세포는 중성지방의 합성, 저장 기능뿐 만 아니라 여러 가지 호르몬, 사이토카인(cytokine) 등의 분비를 통하여 비만과 당뇨 등의 여러 성인성 질환을 유발할 수 있다고 밝혀져 있다. 이러한 지방세포에서 분비되는 아디포카인(adipokines) 으로 레지스틴(resistin, RETN), 아디포넥틴(adiponectin, ADIPOQ) 등이 알려져 있다.Adipose cells are known to be able to induce various adult diseases such as obesity and diabetes through secretion of various hormones and cytokines as well as the synthesis and storage functions of triglycerides. As adipokines secreted from such adipocytes, resistin (RESTin, RETN), adiponectin (ADIPOQ) and the like are known.
상기 레지스틴(resistin, RETN)은 지방의 세포질에 존재하며 유일하게 지방조직에서만 발현되며, PPARγ 의 synthetic ligand인 thialidinedione(TZD) 에 의해 발현이 감소된다고 알려져 있다. 따라서 이들 아디포카인(adipokines)에 대한 발현정도를 분석하였다. Resistin (RESTin) is present in the cytoplasm of fat and is only expressed in adipose tissue, and is known to be reduced in expression by thialidinedione (TZD), a synthetic ligand of PPARγ. Therefore, the expression level of these adipokines was analyzed.
그 결과, 도 12에서도 확인할 수 있듯이 지방세포 분화 유도 시 발현되는 레지스틴(resistin, RETN)은 대두부산물 처리 시 지방세포 분화 유도 대조군에 비해 발현의 차이 크게 나타나지 않았다. As a result, as can be seen in Figure 12, the resistin (resistin, RETN), which is expressed when adipocyte differentiation is induced, did not show a significant difference in expression compared to the adipocyte differentiation control group when soybean by-products were treated.
반면 아디포넥틴(adiponectin, ADIPOQ)은 대두 침지수 및 대두 순물을 처리하였을 때 모든 처리농도 조건에서 mRNA 발현이 급격히 감소하는 것을 확인할 수 있었다. Adiponectin (ADIPOQ), on the other hand, was found to rapidly reduce mRNA expression at all treatment concentrations when soybean immersion and soybean pure were treated.
상기의 결과로부터 대두 침지수 및 대두 순물은 아디포카인(adipokines) 중에서 아디포넥틴(adiponectin, ADIPOQ)의 분비량을 감소시킴으로써 지방세포의 지방생성과 관련된 에너지 대사 조절에 관여하는 것을 확인할 수 있었고, 지방 분화 유도 물질 처리에 의한 전지방세포에서 지방세포로 분화 시 지방세포의 분화 억제 및 지방생성을 억제하는 것을 확인할 수 있었다.From the above results, it was confirmed that soybean immersion water and soybean pure water were involved in regulating energy metabolism related to adipogenesis of adipocytes by reducing the amount of adiponectin (ADIPOQ) in adipokines. It was confirmed that the differentiation of adipocytes and the formation of adipocytes were inhibited when the cells were differentiated into fat cells by treatment.
뿐만 아니라 지방세포의 분화 과정에서 지방대사 및 에너지 대사를 조절하는 adipsin, Fabp4, adiponectin(ADIPOQ) 등의 유전자 발현을 억제하였으며, 이러한 유전자 발현양상은 대두가공 부산물의 처리에 따른 지방세포 분화과정에서 지방함량 정도에 따른 Oil-Red O 염색결과와 일치하여 대두가공 부산물의 처리가 지방합성 단계에서 일부 조절에 관계되고 있음을 확인할 수 있었다.In addition, the expression of adipsin, Fabp4, and adiponectin (ADIPOQ), which regulate fat metabolism and energy metabolism, was inhibited during adipocyte differentiation. Consistent with Oil-Red O staining results, the treatment of soybean by-products was found to be involved in some of the regulation at the liposynthesis stage.
또한, 대두가공 부산물이 PPARγ 발현량을 감소시키는 결과에 비추어 보았을 때 대두가공 부산물이 가지는 지방세포 분화유도의 억제는 분화유도 전사인자의 억제를 통하여 주로 나타나며 동시에 지방세포의 지방생성 억제 효과가 있음을 확인할 수 있었다. In addition, in view of the result of the decrease in the expression of PPARγ by soybean processing by-products, the inhibition of adipocyte differentiation induced by soybean processing by-products appears mainly through the inhibition of differentiation-inducing transcription factors and at the same time, it inhibits adipogenesis of adipocytes. I could confirm it.
결국, 상기의 결과로부터 대두가공 부산물에 의한 지방세포분화 및 지방생성 억제는 지방분화와 지방 대사 조절 관련 유전자의 발현을 통하여 조절되며, 전임상 실험을 통해 결국, 대두가공 부산물은 비만예방 및 억제제로서 유용하게 사용될 수 있음을 확인할 수 있었다.In conclusion, from the above results, the inhibition of adipocyte differentiation and adipogenesis by soybean processing by-products is regulated through the expression of genes related to adipose differentiation and fat metabolism regulation. It could be confirmed that it can be used.
Claims (9)
상기 대두가공 부산물은 대두 침지수(soybean soaking water), 두부 순물(soybean curd whey) 또는 이들의 혼합물인 것을 특징으로 하는 비만 예방 또는 치료용 조성물.The method of claim 1,
The soy processing by-products are soybean soaking water, soybean curd whey or a mixture thereof, characterized in that the composition for preventing or treating obesity.
상기 대두 침지수는 대두를 10 내지 30℃의 온도의 물에 3 내지 24시간 침지하여 수득되는 것을 특징으로 하는 비만 예방 또는 치료용 조성물.The method of claim 2,
The soybean immersion water is a composition for preventing or treating obesity, characterized in that obtained by immersing soybean in water at a temperature of 10 to 30 ℃ for 3 to 24 hours.
상기 유효성분은 전체 조성물 중 0.001 내지 30 중량%인 것을 특징으로 하는 비만 예방 또는 치료용 조성물.3. The method according to claim 1 or 2,
The active ingredient is a composition for preventing or treating obesity, characterized in that 0.001 to 30% by weight of the total composition.
상기 유효성분은 간과 부고환 조직의 지방 변성 및 지방축적 억제; 체내 콜레스테롤의 축적 억제; 중성지방의 축적 억제, 전지방세포의 지방세포로의 분화, 지방세포의 증식; 지방생성의 억제; 아세틸-코에이 카르복실라제(ACC, acetyl-CoA carboxylase)의 활성 억제; 및 AMP 유도 활성화 단백질 키나아제(AMPK, AMP-activated protein kinase)의 활성 증가;로부터 선택되는 1종 이상의 작용에 의해 수행되는 것을 특징으로 하는 비만 예방 또는 치료용 조성물.The method of claim 4, wherein
The active ingredient is fat degeneration and fat accumulation inhibition of liver and epididymal tissue; Inhibition of accumulation of cholesterol in the body; Inhibition of the accumulation of triglycerides, differentiation of fat cells into adipocytes, proliferation of adipocytes; Inhibition of lipogenesis; Inhibition of the activity of acetyl-CoA carboxylase (ACC); And increasing the activity of AMP-induced activated protein kinase (AMPK). The composition for preventing or treating obesity, characterized in that it is carried out by at least one action selected from.
상기 유효성분은 퍼옥시좀 증식인자 활성화 수용체 감마(PPARγ, peroxisome proliferator activated receptor)의 활성을 저해하는 것을 특징으로 하는 비만 예방 또는 치료용 조성물.6. The method of claim 5,
The active ingredient is a composition for preventing or treating obesity, characterized in that it inhibits the activity of peroxysome growth factor activating receptor gamma (PPARγ, peroxisome proliferator activated receptor).
상기 조성물은 하나 이상의 약학적으로 허용되는 담체 또는 부형제를 포함하는 것을 특징으로 하는 비만 예방 또는 치료용 조성물.3. The method according to claim 1 or 2,
The composition is a composition for preventing or treating obesity, characterized in that it comprises one or more pharmaceutically acceptable carriers or excipients.
상기 건강보조 식품은 드링크제, 캬라멜, 쵸콜릿, 다이어트바 제형, 및 과자류로부터 선택되는 1종 이상인 것을 특징으로 하는 비만 예방 또는 치료용 건강 보조 식품.The method of claim 8,
The dietary supplement is a dietary supplement for the prevention or treatment of obesity, characterized in that at least one selected from drink, caramel, chocolate, diet bar formulation, and confectionary.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110025594A KR101356398B1 (en) | 2011-03-23 | 2011-03-23 | Composition containing soybean by product for anti-obesity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110025594A KR101356398B1 (en) | 2011-03-23 | 2011-03-23 | Composition containing soybean by product for anti-obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120108071A true KR20120108071A (en) | 2012-10-05 |
KR101356398B1 KR101356398B1 (en) | 2014-01-29 |
Family
ID=47279722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110025594A KR101356398B1 (en) | 2011-03-23 | 2011-03-23 | Composition containing soybean by product for anti-obesity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101356398B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547829A (en) * | 2015-02-03 | 2015-04-29 | 苏少中 | Traditional Chinese medicine composition for treating fatty liver |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050059860A (en) * | 2003-12-15 | 2005-06-21 | 학교법인 경영교육재단 | Composition comprising microorganism having antidiabetes for prevention and treatment of obeseness and the use thereof |
KR20100028616A (en) * | 2010-02-22 | 2010-03-12 | (주)아모레퍼시픽 | Oral compositions for the improvement of obesity |
-
2011
- 2011-03-23 KR KR1020110025594A patent/KR101356398B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547829A (en) * | 2015-02-03 | 2015-04-29 | 苏少中 | Traditional Chinese medicine composition for treating fatty liver |
Also Published As
Publication number | Publication date |
---|---|
KR101356398B1 (en) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hadrich et al. | Evaluation of hypocholesterolemic effect of oleuropein in cholesterol-fed rats | |
Bunkrongcheap et al. | Ivy gourd (Coccinia grandis L. Voigt) root suppresses adipocyte differentiation in 3T3-L1 cells | |
Kim et al. | Green tea seed oil reduces weight gain in C57BL/6J mice and influences adipocyte differentiation by suppressing peroxisome proliferator-activated receptor-γ | |
Kim et al. | Antihyperglycemic and antihyperlipidemic effects of fermented Rhynchosia nulubilis in alloxan-induced diabetic rats | |
US20130102554A1 (en) | Composition for treatment of obesity using wheat bran extract or active ingredient isolated therefrom | |
TW201309313A (en) | Adiponectin production promoter, and pharmaceutical composition, food and drink, and fodder containing adiponectin production promoter | |
KR101356398B1 (en) | Composition containing soybean by product for anti-obesity | |
KR20150083622A (en) | Anti-obesity composition using acanthopanax sessiliflorus and mulberry | |
JP2007291081A (en) | Composition having bone resorption inhibition-related effect | |
Kim et al. | Ethanol extracts of unroasted Coffea canephora robusta beans suppress adipogenesis in preadipocytes and fat accumulation in rats fed a high-fat diet | |
KR20210099482A (en) | Obesity prevention or treatment composition using soybean processing by-product as an active ingredient | |
KR20070068837A (en) | Extracts from the seed of rosa multiflora for inhibiting the differentiation of adipocytic cells | |
KR20160094313A (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
KR102160627B1 (en) | Pharmaceutical composition for preventing or treating bone disease comprising extracts of branches of Hovenia dulcis Thunb | |
KR101781468B1 (en) | ChangmacTang Composition Having Antihyperlipidemic Effect and Preparing Method Thereof | |
US9737502B2 (en) | Calebin A for hepatic steatosis | |
KR20150091770A (en) | Composition for treating or preventing obesity containing caulerpa okamurai | |
JP2020535222A (en) | Composition for weight control by regulating peptide levels involved in satiety and / or appetite | |
KR101542694B1 (en) | Composition comprising water extract of hulled barley for preventing and treating obesity | |
KR102269820B1 (en) | Pharmaceutical composition comprising the extract of cannabis sativa as an effective ingredient for preventing or treating of obesity | |
KR102621399B1 (en) | Composition of antler and schisandra complex powder for growth promotion and and method for preparing the same | |
KR102567179B1 (en) | Composition for enhancement of exercise performance comprising gypenoside compounds as an active ingredient | |
KR100898832B1 (en) | Composition for anti-obesity | |
KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
JP2015214542A (en) | Calebin a for steatosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170124 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180123 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |